Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. (symbol: OM) is a pioneering medical technology company committed to revolutionizing the dialysis experience. The company’s primary product, Tablo, is an innovative dialysis machine designed to simplify and streamline the process of Renal Replacement Therapy. By focusing on a patient-centric approach, Outset Medical places patient care, ease of use, and cost-efficiency at the forefront of its operations.
The Tablo dialysis system is built with a user-friendly touchscreen display that offers step-by-step visual and conversational instructions, making it accessible to both patients and caregivers, regardless of their experience level. This intuitive design dramatically reduces the complexity and cost associated with traditional dialysis treatments. Tablo can be used across various settings, including hospitals, chronic care dialysis clinics, and at home, making it a versatile solution for renal care.
Outset Medical’s mission is to improve the care experience for patients, families, providers, and physicians, while also enhancing cost-efficiencies for healthcare providers. The company achieves this by combining expertise from different healthcare fields, fostering an environment of cross-disciplinary innovation. This approach has led to significant advancements in dialysis technology and patient care.
Recent achievements include regulatory approvals and partnerships aimed at expanding Tablo’s reach and improving its functionalities. Financially, Outset Medical has shown robust growth, supported by a dedicated team of professionals and continuous innovation in their product offerings. The company's efforts are geared towards giving people their time back by reducing the dialysis process's complexity and duration.
Stay updated with the latest developments and news about Outset Medical, Inc. to learn how this industry leader is transforming renal care.
Outset Medical, Inc. (Nasdaq: OM), a leader in medical technology, will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference on March 8, 2022, at 11:50 AM PT. This event will provide insights into their groundbreaking Tablo Hemodialysis System, designed to simplify dialysis and reduce costs. A live and archived webcast will be available on the Outset Medical website. Tablo allows for dialysis to be administered easily across various settings, transforming patient care and operational efficiency.
Outset Medical, Inc. (Nasdaq: OM) reported record annual revenue of $102.6 million for 2021, marking a 105.5% year-over-year growth. The fourth quarter revenue reached $28.2 million, up 63.2% from the previous year. The company achieved a gross margin of 11.8% in Q4, improving significantly from 2.4% in Q4 2020. Operating expenses for 2021 were $138.1 million, with a net loss of ($131.9 million). Looking ahead, Outset projects revenue for 2022 between $142 million and $150 million, indicating further growth.
Outset Medical, Inc. (Nasdaq: OM) announced management participation in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 12:40pm PT / 3:40pm ET. The event will be accessible via a live and archived webcast on Outset's website. Outset Medical is revolutionizing dialysis with its Tablo Hemodialysis System, which simplifies treatment and reduces costs. This FDA-cleared technology enables delivery of dialysis anywhere by utilizing integrated water purification and on-demand dialysate production.
Outset Medical, Inc. (Nasdaq: OM) will announce its financial results for Q4 and the full year of 2021 after market close on February 16, 2022. A conference call will follow at 2:00 PM PT (5:00 PM ET), led by CEO Leslie Trigg and CFO Nabeel Ahmed. The call can be accessed by dialing specific numbers for domestic and international callers. Outset's Tablo® Hemodialysis System aims to simplify dialysis with its innovative technology, making treatment accessible and efficient across various settings.
Outset Medical, Inc. (NASDAQ: OM) has received FDA clearance for a new sterilization method of the Tablo Hemodialysis System cartridge. This advancement allows production to shift to North America, particularly Mexico, which is expected to reduce costs and enhance supply chain reliability. The new method is eco-friendly, utilizing e-beam technology. CEO Leslie Trigg highlighted that this milestone aims to improve gross margins while addressing manufacturing challenges and logistics.
Outset Medical, Inc. (NASDAQ: OM) has been named in Fast Company’s inaugural Next Big Things in Tech list, recognizing its groundbreaking Tablo® Hemodialysis System.
This innovative dialysis solution simplifies treatment and reduces costs, making it easier for patients and providers. Tablo combines advanced features like wireless connectivity and integrated water purification into a single unit. CEO Leslie Trigg emphasizes the importance of consumer-centric design in improving the dialysis experience. This recognition reflects Outset's commitment to revolutionizing dialysis care.
Outset Medical reported Q3 2021 net revenue of $26.3 million, a 91.3% increase from $13.8 million in Q3 2020. The gross margin improved to 11.2%, up from (37.3%) year-over-year. Full year 2021 revenue guidance was raised to $99 million to $101 million, indicating 98% to 102% growth over 2020. The company recorded a net loss of ($30.5 million), or ($0.65) per share, significantly better than the previous year’s loss. Cash stood at $406.4 million as of September 30, 2021.
Outset Medical, Inc. (Nasdaq: OM) announced management's participation in a fireside chat at the Stifel 2021 Virtual Health Care Conference on November 16, 2021, at 1:40 PM PT. The event will be available via a live and archived webcast on Outset's Investors section. Outset Medical is revolutionizing dialysis with the Tablo Hemodialysis System, making it easier and more cost-effective for patients and providers. This innovative technology enables dialysis to be administered anywhere, incorporating advanced data analytics and operational simplicity.
Outset Medical, Inc. (Nasdaq: OM) has received approval for its Tablo® Hemodialysis System from the Centers for Medicare & Medicaid Services for the Transitional Add-on Payment Adjustment for New and Innovative Equipment and Supplies (TPNIES). This approval aims to enhance home dialysis accessibility for patients with end-stage renal disease. Over the next two years, healthcare providers can receive supplemental reimbursements, promoting wider adoption of Tablo. The approval follows strong support from healthcare providers and patients, emphasizing the system’s ease of use and potential for better patient outcomes.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
What is Outset Medical, Inc.?
What product does Outset Medical offer?
How does the Tablo dialysis system work?
In what settings can Tablo be used?
What is the company's main mission?
Who can use the Tablo machine?
What is unique about the Tablo machine?
How does Outset Medical foster innovation?
What recent achievements does Outset Medical have?
How has Outset Medical performed financially?
